Abstract
Isosorbide dinitrate (ISDN) is widely used for the treatment of angina pectoris and has been shown to prolong exercise tolerance during acute and sustained therapy [1–8]. However, ISDN is poorly bioavailable after oral intake, and a marked inter-individual variation in plasma ISDN concentrations has been reported after oral doses during both acute and chronic therapy [4]. After oral ingestion, ISDN is rapidly metabolized into 2- and 5-mononitrates, both of which are biologically active. Now commercially available in Europe, isosorbide-5-mononitrate (IS-5-MN) has a half-life of 4–6 h and is almost 100% bioavailable after oral ingestion [9]. The latter makes this compound pharmacokinetically more desirable than its parent compound ISDN. Furthermore, a slow-release formulation of IS-5-MN providing high plasma levels for up to 24 h is now available which should theoretically offer advantages by exerting antianginal effects over a prolonged period of time.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Glancy DL, Ritcher MA, Ellis EV, Johnson W (1977) Effect of swallowed isosorbide dinitrate on blood pressure, heart rate, and exercise capacity in patients with coronary artery disease. Am J Med 62:39
Danahy DT, Aronow WS (1977) Hemodynamic and antianginal effects of high-dose oral isosorbide dinitrate after chronic use. Circulation 56:205
Danahy DT, Burwell DT, Aronow WS, Prakash R (1977) Sustained hemodynamic and antianginal effects of high oral dose isosorbide dinitrate. Circulation 55:381
Thadani U, Fung H-L, Darke AC, Parker JO (1982) Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response relationship during acute and sustained therapy. Am J Cardiol 219:411
Thadani U (1984) Nitrates for angina pectoris: a critical review of therapeutic efficacy and tolerance. Herz 9:123
Lee G, Mason DT, Amsterdam EA, Miller RR, Demaria AM (1978) Antianginal efficacy of oral therapy with isosorbide dinitrate capsules: prolonged benefit shown by exercise testing in patients with ischemic heart disease. Chest 73:327
Rudolph W, Blasini R, Froer KL, Brügmann U, Mannes A, Hall D (1981) Effects of acute and chronic administration of isosorbide dinitrate, sustained-release form, in patients with angina pectoris. In: Lichtlen PR, Engel H-J, Schrey A, Swan HJC (eds) Nitrates III. Springer, Berlin Heidelberg New York, p 75
Schneider W, Wietschoreck, Bussmann WD, Kaltenbach M (1983) Sustained antianginal efficacy of high-dose isosorbide dinitrate in patients with coronary heart disease. Z Kardiol 72 [Suppl 3]:259
Chasseaud LF, Taylor T (1981) Pharmacokinetics of isosorbide-5-mononitrate. In: Kaltenbach, Bussmann, Schrey (eds) Mononitrate workshop. Wolf, Munich, p 12
Thadani U, Hamilton S, Teague S, Brady D, White B (to be published) Circulatory and antianginal effects of isosorbide-5-mononitrate: slow-release formulation in angina pectoris.
Parker JO, Vankoughnett KA, Fung H-L (1984) Transdermal isosorbide dinitrate in angina pectoris: effects of acute and sustained therapy. Am J Cardiol 54:8
Tauchert M, Jansen W, Osterspey A, Fuchs M, Hombach V, Hilger HH (1983) Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 72 [Suppl 3]:218
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Thadani, U., Hamilton, S., Teague, S., Brady, D., White, B. (1985). Slow-Release Isosorbide-5-Mononitrate for the Treatment of Angina Pectoris: Duration of Effects. In: Cohn, J.N., Rittinghausen, R. (eds) Mononitrates. International Boehringer Mannheim Symposia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70234-1_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-70234-1_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-15107-4
Online ISBN: 978-3-642-70234-1
eBook Packages: Springer Book Archive